102 Alternatively, various teams are advocating to the incorporation of novel markers, such as a complex karyotype55 or epigenetic subsets, 27,28 into medical observe. All these novel prognostic and/or predictive products will must be validated in cohorts of sufferers treated with qualified brokers.Some degree of immunophenotype overlap amongst CLL